It is very uncertain whether irinotecan changes overall survival ‐ Other comparisons compared with non‐irinotecan‐containing regimens (very low certainty).
Irinotecan may leads to higher tumour response compared with non‐irinotecan‐containing regimens (low certainty).
Irinotecan leads to lower progression‐free survival compared with non‐irinotecan‐containing regimens (high certainty).
Irinotecan showed no clear difference in progression‐free survival ‐ Substitutive comparison compared with non‐irinotecan‐containing regimens (moderate certainty).
Irinotecan showed no clear difference in treatment‐related death compared with non‐irinotecan‐containing regimens (low certainty).
It is very uncertain whether irinotecan changes treatment discontinuation due to toxicity compared with non‐irinotecan‐containing regimens (very low certainty).
Docetaxel leads to lower overall survival compared with non‐docetaxel‐containing regimens (high certainty).
Docetaxel showed no clear difference in overall survival ‐ Substitutive comparisons compared with non‐docetaxel‐containing regimens (moderate certainty).
Docetaxel probably leads to lower overall survival ‐ Additive comparisons compared with non‐docetaxel‐containing regimens (moderate certainty).
It is very uncertain whether docetaxel changes overall survival ‐ Other comparisons compared with non‐docetaxel‐containing regimens (very low certainty).
Docetaxel probably leads to higher tumour response compared with non‐docetaxel‐containing regimens (moderate certainty).
It is very uncertain whether docetaxel changes time to progression compared with non‐docetaxel‐containing regimens (very low certainty).
Docetaxel probably leads to lower progression‐free survival compared with non‐docetaxel‐containing regimens (moderate certainty).
It is very uncertain whether docetaxel changes progression‐free survival ‐ Substitutive comparisons compared with non‐docetaxel‐containing regimens (very low certainty).
Docetaxel showed no clear difference in treatment‐related death compared with non‐docetaxel‐containing regimens (moderate certainty).
Docetaxel showed no clear difference in treatment discontinuation due to toxicity compared with non‐docetaxel‐containing regimens (low certainty).
Capecitabine showed no clear difference in overall Survival compared with 5‐FU‐containing regimens (moderate certainty).
It is very uncertain whether capecitabine changes tumour response compared with 5‐FU‐containing regimens (very low certainty).
It is very uncertain whether capecitabine changes time to progression compared with 5‐FU‐containing regimens (very low certainty).
It is very uncertain whether capecitabine changes progression‐free survival compared with 5‐FU‐containing regimens (very low certainty).